What to Tell Patients With Rheumatic/Musculoskeletal Diseases About COVID Vaccines

What to Tell Patients With Rheumatic/Musculoskeletal Diseases About COVID Vaccines

The American College of Rheumatology (ACR) has issued a guidance document about COVID-19 vaccinations for patients with rheumatic and musculoskeletal diseases (RMDs). Included is information on general concerns and foundational principles, timing of vaccination, and adaptations to therapy. ACR cautioned, however, that the recommendations are still conditional and are based on indirect evidence derived from…

Op-Ed: Mind the Ketamine Education Gap

Op-Ed: Mind the Ketamine Education Gap

Ketamine treatment has received a lot of attention in recent months. In research studies, ketamine has been shown to be helpful in the treatment of refractory depression, bipolar depression, and obsessive-compulsive disorder, in addition to a variety of refractory pain disorders. More studies are underway looking at additional psychiatric and psychological indications for ketamine treatment.…

New Oral Agent Approved for Relapsing Multiple Sclerosis

New Oral Agent Approved for Relapsing Multiple Sclerosis

The FDA approved oral ponesimod (Ponvory) to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, drugmaker Janssen announced Friday. Ponesimod is a selective modulator of the sphingosine-1 phosphate receptor, like two other approved MS drugs, fingolimod (Gilenya) and siponimod (Mayzent). Binding of the drug to…